Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

5.390 +0.310 (+6.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,402,635
Open 5.080
Bid (Size) 5.300 (200)
Ask (Size) 5.400 (300)
Prev. Close 5.080
Today's Range 5.010 - 5.409
52wk Range 2.930 - 7.550
Shares Outstanding 38,886,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aquestive (AQST) Q2 2026 Earnings Call Transcript ↗
Revenue grew 38% year-over-year to $13.8 million as Anaphylm resubmission nears. 
Via The Motley Fool
Topics Earnings
News headline image
Aquestive Therapeutics Q2 Earnings Call Highlights ↗
Aquestive Therapeutics (NASDAQ:AQST) said it plans to resubmit its new drug application for Anaphylm, its epinephrine sublingual film candidate for type 1 allergic reactions including anaphylaxis,... 
Via MarketBeat
Topics Earnings

Performance

YTD
-16.4%
-16.4%
1 Month
+44.5%
+44.5%
3 Month
+32.1%
+32.1%
6 Month
+31.8%
+31.8%
1 Year
+39.6%
+39.6%

More News

Read More
News headline image
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
AQST Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Aquestive Therapeutics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
AQUESTIVE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff Role
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff Role
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
From Pomerantz LLP
Via GlobeNewswire
News headline image
AQUESTIVE DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors They Have Until May 4th to Seek Lead Plaintiff Role
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
From Pomerantz LLP
Via GlobeNewswire
News headline image
Robbins LLP Urges AQST Stockholders to Contact the Firm for Information About the Class Action Against Aquestive Therapeutics, Inc.
From Robbins LLP
Via Business Wire
News headline image
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
From Pomerantz LLP
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors They Have Until May 4th to Seek Lead Plaintiff Role
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is Aquestive Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aquestive Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aquestive Therapeutics, Inc. - Common Stock trade on?
Aquestive Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aquestive Therapeutics, Inc. - Common Stock?
The ticker symbol for Aquestive Therapeutics, Inc. - Common Stock is AQST on the Nasdaq Stock Market
What is the current price of Aquestive Therapeutics, Inc. - Common Stock?
The current price of Aquestive Therapeutics, Inc. - Common Stock is 5.390
When was Aquestive Therapeutics, Inc. - Common Stock last traded?
The last trade of Aquestive Therapeutics, Inc. - Common Stock was at 08/26/26 04:00 PM ET
What is the market capitalization of Aquestive Therapeutics, Inc. - Common Stock?
The market capitalization of Aquestive Therapeutics, Inc. - Common Stock is 209.60M
How many shares of Aquestive Therapeutics, Inc. - Common Stock are outstanding?
Aquestive Therapeutics, Inc. - Common Stock has 210M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.